{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:58:09Z","timestamp":1784548689045,"version":"3.55.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.clbc.2023.07.006","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T14:48:33Z","timestamp":1690382913000},"page":"e458-e469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper"],"prefix":"10.1016","volume":"23","author":[{"given":"Mattia","family":"Garutti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cucciniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Munzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Staropoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2023.07.006_bib0001","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2023.07.006_bib0002","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2023.07.006_bib0003","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1093\/annonc\/mdm271","article-title":"Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007","volume":"18","author":"Goldhirsch","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0004","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2023.07.006_bib0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.07.006_bib0006","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.07.006_bib0007","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.07.006_bib0008","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.07.006_bib0011","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0012","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","article-title":"GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations","volume":"66","author":"Andrews","year":"2013","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18","volume":"2001","author":"Wolmark","year":"2001","journal-title":"JNCI Monogr"},{"key":"10.1016\/j.clbc.2023.07.006_bib0014","first-page":"37","article-title":"NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel","volume":"11","author":"Mamounas","year":"1997","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clbc.2023.07.006_bib0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","article-title":"Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2023.07.006_bib0016","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1200\/JCO.19.00066","article-title":"Seven-year follow-up analysis of adjuvant Paclitaxel and Trastuzumab trial for node-negative, human epidermal growth factor receptor 2\u2013positive breast cancer","volume":"37","author":"Tolaney","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0017","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2217\/fon-2016-0420","article-title":"The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis","volume":"13","author":"Chen","year":"2017","journal-title":"Futur Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0018","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.4048\/jbc.2012.15.2.203","article-title":"Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy","volume":"15","author":"Yoo","year":"2012","journal-title":"J Breast Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0020","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2023.07.006_bib0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-010-1103-9","article-title":"Effect of neoadjuvant anthracycline\u2013taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study","volume":"124","author":"Huober","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2023.07.006_bib0022","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-015-3479-z","article-title":"Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials","volume":"152","author":"Loibl","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2023.07.006_bib0023","article-title":"NCCN Guidelines Version 4.2022","volume":"1","author":"Rashmi Kumar","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0024","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0025","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","article-title":"Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27","volume":"26","author":"Rastogi","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0026","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/jnci\/dji021","article-title":"Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis","volume":"97","author":"Mauri","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2023.07.006_bib0027","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S1470-2045(13)70411-X","article-title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomized phase 3 trial","volume":"14","author":"Robidoux","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100433","article-title":"Survival after neoadjuvant therapy with trastuzumab\u2013lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials","volume":"7","author":"Guarneri","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2023.07.006_bib0029","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","article-title":"Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomized phase 3 trial","volume":"13","author":"Untch","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0030","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1200\/JCO.2017.75.9175","article-title":"Survival analysis after neoadjuvant chemotherapy with Trastuzumab or Lapatinib in patients with human epidermal growth factor receptor 2\u2013positive breast cancer in the GeparQuinto (G5) study (GBG 44)","volume":"36","author":"Untch","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0031","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2011.35.0868","article-title":"Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31","volume":"29","author":"Perez","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0032","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomized multicenter, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0033","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicenter, open-label, phase 2 randomized trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0034","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","article-title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive ea","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0035","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0036","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdw610","article-title":"Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial","volume":"28","author":"Loibl","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0037","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.20.01204","article-title":"Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 Years\u2019 follow-up","volume":"39","author":"Piccart","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0038","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/S0140-6736(18)33137-4","article-title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomized trials","volume":"393","author":"Gray","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2023.07.006_bib0039","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/ijc.32789","article-title":"Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial","volume":"147","author":"Lambertini","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0040","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/cncr.32653","article-title":"Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: results from the phase 3 PANTHER trial","volume":"126","author":"Papakonstantinou","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-021-00284-y","article-title":"Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab","volume":"7","author":"Wang","year":"2021","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0042","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.07.006_bib0043","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicenter, open-label, randomized, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0044","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1634\/theoncologist.2012-0057","article-title":"Weekly Paclitaxel\/Carboplatin\/Trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-b subtype, compared with a once-every-3-weeks schedule","volume":"18","author":"Yu","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2023.07.006_bib0045","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2006.09.9994","article-title":"Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial","volume":"25","author":"Coudert","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0046","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211006948","article-title":"Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis","volume":"13","author":"Zhang","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0047","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.3692","article-title":"Efficacy, safety, and tolerability of Pertuzumab, Trastuzumab, and Docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial","volume":"6","author":"Shao","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0048","first-page":"517","article-title":"Neoadjuvant weekly paclitaxel with and without trastuzumab in locally advanced or metastatic breast cancer","volume":"29","author":"Horiguchi","year":"2009","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clbc.2023.07.006_bib0049","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.07.006_bib0050","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(22)00159-0","volume":"23","author":"Nitz","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0051","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2023.07.006_bib0052","first-page":"6110","article-title":"Loss of HER2 and disease prognosis after neoadjuvant treatment of HER2+ breast cancer","volume":"11","author":"Branco","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.clbc.2023.07.006_bib0053","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/annonc\/mdv611","article-title":"Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry","volume":"27","author":"Niikura","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0054","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/jso.26646","article-title":"Loss of HER2-positivity following neoadjuvant targeted therapy for breast cancer is not associated with inferior oncologic outcomes","volume":"124","author":"Wetzel","year":"2021","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0055","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2021.05.802","article-title":"Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0056","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.annonc.2020.03.036","article-title":"96O Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: subgroup analysis from KATHERINE","volume":"31","author":"Loibl","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0057","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0058","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.clbc.2020.09.014","article-title":"Final efficacy results of Neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial","volume":"21","author":"Chan","year":"2021","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0059","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0060","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2014.58.7782","article-title":"Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer","volume":"33","author":"Krop","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0061","first-page":"895","article-title":"Adjuvant Trastuzumab Emtansine (T-DM1) and concurrent radiotherapy for residual invasive HER2-positive Breast Cancer: single-center preliminary results","volume":"43","author":"Zolcs\u00e1k","year":"2020","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"10.1016\/j.clbc.2023.07.006_bib0062","article-title":"Safety of concurrent TDM-1 and radiotherapy for patients with residual HER2-positive breast cancer","volume":"1","author":"Becherini","year":"2021","journal-title":"ESTRO PO-1096"},{"key":"10.1016\/j.clbc.2023.07.006_bib0063","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1158\/1078-0432.CCR-18-2851","article-title":"Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4","volume":"25","author":"Stumpf","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2023.07.006_bib0064","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-016-2265-z","article-title":"Preliminary experience of the concurrent use of radiosurgery and T-DM1 for brain metastases in HER2-positive metastatic breast cancer","volume":"131","author":"Geraud","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0065","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12885-021-07971-w","article-title":"Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases","volume":"21","author":"Mills","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0066","first-page":"93","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2023.07.006_bib0067","doi-asserted-by":"crossref","unstructured":"Romond E, Suman V, Jeong J-H, et\u00a0al. Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. American Association for Cancer Research (AACR); 2012, p. S5-5-S5-5. https:\/\/doi.org\/10.1158\/0008-5472.sabcs12-s5-5.","DOI":"10.1158\/0008-5472.SABCS12-S5-5"},{"key":"10.1016\/j.clbc.2023.07.006_bib0068","article-title":"VP6-2022: adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years\u2019 follow-up","volume":"0","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.clbc.2023.07.006_bib0069","doi-asserted-by":"crossref","first-page":"dju152","DOI":"10.1093\/jnci\/dju152","article-title":"Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer","volume":"106","author":"Prat","year":"2014","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2023.07.006_bib0070","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1002\/cncr.31657","article-title":"Optimal treatment of early stage HER2-positive breast cancer","volume":"124","author":"Pernas","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0071","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s13058-014-0427-5","article-title":"Biology of breast cancer in young women","volume":"16","author":"Azim","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2023.07.006_bib0072","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2012.44.1956","article-title":"Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2\u2013positive breast cancer: results from a Herceptin adjuvant trial","volume":"31","author":"Partridge","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0073","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2023.07.006_bib0074","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/jnci\/djac096","article-title":"Impact of age on Clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy","volume":"114","author":"Lambertini","year":"2022","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2023.07.006_bib0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2022.01.031","volume":"166","author":"Gelber","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2023.07.006_bib0076","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","article-title":"Fluorouracil, Epirubicin, and Cyclophosphamide with either Docetaxel or Vinorelbine, with or without Trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial","volume":"27","author":"Joensuu","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0077","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/S0140-6736(19)30653-1","article-title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicenter, open-label, phase 3 randomized trial","volume":"393","author":"Pivot","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2023.07.006_bib0078","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1093\/annonc\/mdy414","article-title":"Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study","volume":"29","author":"Conte","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0079","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamaoncol.2018.1380","article-title":"Effect of adjuvant Trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2\u2013positive breast cancer","volume":"4","author":"Joensuu","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2023.07.006_bib0080","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923002021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820923002021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:25:19Z","timestamp":1761513919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820923002021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1526820923002021"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2023.07.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2023.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}